Dry Needling and Botulinum Toxin in the Management of Poststroke Spasticity

• Status: Completed
• Trial end date: 2018-03-30
• Target enrollment: 0
• Participant gender: All

Summary

Stroke is a clinical picture that can result in loss of motor, sensory and cognitive functions or coma. Approximately 75% of stroke survivors develop disability and one of the causes of disability is the presence of spasticity. Effective treatment of spasticity accelerates functional recovery. Botulinum toxin type A (BTX-A) injection is a safe and effective method in the management of focal spasticity. As its effects over central and peripheral nervous system have been understood, dry needling has been recently introduced as the novel treatment of spasticity after stroke in clinical practice. Studies evaluating the efficacy of dry needling in the treatment of spasticity are limited in the literature and there is no data on the long-term efficacy of dry needling in current studies. On the other hand, the effects of dry needling when combined with other antispastic treatment modalities have not been investigated yet. In this study, the antispastic efficacy of dry needling applied with BTX-A injection was investigated.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey
• Treatments: abobotulinumtoxinA; Botulinum Toxins; Botulinum Toxins, Type A; onabotulinumtoxinA

Criteria

Inclusion Criteria:

• Patients with first-time stroke

• To have Modified Ashworth Scale of 2 and 3 spasticity levels in the elbow flexor muscles of the hemiplegic side

• Not having any joint pathology that would prevent passive movements of the involved elbow joint

Exclusion Criteria:

• Having a mental problem

• Presence of cooperation-orientation limitation or neglect

• Use of an oral antispastic agent

• BTX-A application in the last 3 months

• Peripheral nerve injury in the affected side upper extremity

• Wound presence in the area where the procedure will be applied

• Patients with a contraindication for BTX-A application

• Patients with needle phobia